1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111540
    LY-3381916
    Inhibitor 99.92%
    LY-3381916 (IDO1-IN-5) is a potent, selective and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
    LY-3381916
  • HY-131911
    PROTAC IDO1 Degrader-1
    Inhibitor 99.00%
    PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells.
    PROTAC IDO1 Degrader-1
  • HY-N0110B
    Palmatine hydroxide
    Inhibitor 99.64%
    Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine hydroxide
  • HY-N7688
    Regaloside B
    Inhibitor 99.90%
    Regaloside B is a phenylpropane. Regaloside B can be isolated from Lilium longiflorum. Regaloside B can inhibit the expression of VCAM-1, iNOS, and COX-2, with a p-p65/p-65 ratio. Regaloside B inhibits the mRNA of various chemokines and angiogenic factors (CXCL9, CXCL10, IL8, IDO). Regaloside B has anti-inflammatory activity. Regaloside B can be used for osteogenic differentiation research.
    Regaloside B
  • HY-148383
    DP00477
    Inhibitor 98.21%
    DP00477 is a potent IDO1 (indoleamine 2,3-dioxygenase 1) inhibitor with an IC50 value of 7.0 µM. DP00477 has the potential for the research of cancer.
    DP00477
  • HY-144651
    IDO1-IN-18
    Inhibitor 98.77%
    IDO1-IN-18 (Compound 14) is a potent inhibitor of IDO1. IDO1-IN-18 has the potential for the research of cancer diseases.
    IDO1-IN-18
  • HY-N0430A
    Coptisine Sulfate
    Inhibitor 99.37%
    Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease.
    Coptisine Sulfate
  • HY-100771
    PCC0208009
    Inhibitor 98.06%
    PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .
    PCC0208009
  • HY-15683
    IDO5L
    Inhibitor 99.89%
    IDO5L is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 67 nM.
    IDO5L
  • HY-177086
    IDO1/TDO-IN-9
    Inhibitor 99.54%
    IDO1/TDO-IN-9 (Compound 66) is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) with IC50s of <1 μM. IDO1/TDO-IN-9 inhibits the activity of IDO1 and TDO, blocking tryptophan degradation to kynurenine, restoring immune activity in the tumor microenvironment, and suppressing tumor growth. IDO1/TDO-IN-9 is promising for research of cancers.
    IDO1/TDO-IN-9
  • HY-151425
    TDO-IN-1
    Inhibitor 98.67%
    TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo.
    TDO-IN-1
  • HY-100687
    GNF-PF-3777
    Inhibitor 98.03%
    GNF-PF-3777 (8-Nitrotryptanthrin) is a potent human indoleamine 2,3-dioxygenase 2 (hIDO2) inhibitor which significantly reduces IDO2 activity with Ki of 0.97 μM.
    GNF-PF-3777
  • HY-128355
    IDO/TDO-IN-1
    Inhibitor 99.30%
    IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
    IDO/TDO-IN-1
  • HY-145346
    NLG802
    Inhibitor 98.77%
    NLG802 is a proagent of indoximod, an orally active indoleamine 2,3-dioxygenase (IDO) inhibitor.
    NLG802
  • HY-15689R
    Epacadostat (Standard)
    Inhibitor
    Epacadostat (Standard) is the analytical standard of Epacadostat. This product is intended for research and analytical applications. Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM.
    Epacadostat (Standard)
  • HY-145280
    IDO1/2-IN-1
    Inhibitor 98.06%
    IDO1/2-IN-1 (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 exhibits antitumor activies. Orally active.
    IDO1/2-IN-1
  • HY-144652
    IDO1-IN-19
    Inhibitor 98.82%
    IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases.
    IDO1-IN-19
  • HY-151886
    NU223612
    Inhibitor 99.41%
    NU223612 is a potent PROTAC (PROTACs) that degrades indoleamine 2,3-dioxygenase 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)) with a Kd of 640 nM. NU223612 potently degrades the IDO1 protein through CRBN-mediated proteasomal degradation. NU223612 is bound to CRBN with an affinity of 290 nM. NU223612 can cross the blood-brain barrier (BBB).
    NU223612
  • HY-W113615
    4-Phenyl-1H-1,2,3-triazole
    Inhibitor 99.35%
    4-Phenyl-1H-1,2,3-triazole is an IDO1 inhibitor (IC50: 60 μM). 4-Phenyl-1H-1,2,3-triazole can be used for cancer research.
    4-Phenyl-1H-1,2,3-triazole
  • HY-115122
    IDO-IN-12
    Inhibitor 99.22%
    IDO-IN-12 is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO 2017181849 A1.
    IDO-IN-12
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.